This buy increased the fund’s VBIL stake to 1.15% of its 13F reportable assets under management. Top holdings after the filing: NYSEMKT:DFAC: $360.73 million (45.6% of AUM) NYSEMKT:DFIC: $65.15 ...
This story is part of a series on the current progression in Regenerative Medicine. This piece is part of a series dedicated to the eye and improvements in restoring vision. In 1999, I defined ...
A study showed that survivors of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) had an increased risk for cardiovascular morbidity and mortality, which peaked within the first ...
In terms of technicals, the relative strength index (RSI) of SJS Enterprises stands at 56.8, signaling it's trading neither in the overbought zone nor in the oversold zone. SJS Enterprises stock has a ...
The retrospective study of patient hospital data showed that current approaches to identifying a culprit drug often overidentify drugs unlikely to be responsible for Stevens-Johnson syndrome/toxic ...
Naredi will be responsible for finance and accounts, fund-raising, purchases, investor relations and liaisoning with investors and bankers. He will be responsible for finance and accounts, ...
Shares of SJS Enterprises on Monday made a tepid debut against the issue price of Rs 542. On BSE, it listed at Rs 540, a decline of 0.36 per cent from the issue price. It then dipped 6.13 per cent to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results